

Thursday, October 26, 2006

9:30 – 11:00 Redefining Treatment Expectations in Moderate-to-Severe Psoriasis

Room: Macdonald ABCD, Fairmont Chateau Whistler Resort

Session Objectives:

Dermatologists participating in this symposium will:

- Discuss practical management issues with biologic agents in the treatment of psoriatic disease based on extensive US experience,
- Recognize the key safety issues with TNF antagonists currently available in Canada,
- Obtain pearls on how to incorporate biologics into their own practice through an interactive panel discussion

Faculty:

Dr. Kim Papp, Chair
Dr. Brian Feagan
Dr. Kristian Reich
Dr. Kam Shojania
Dr. Norman Wasel

Agenda:

- The Use of TNF Blockers in Chronic Inflammatory Disease: What are the Important Safety Issues? – Dr. Brian Feagan
- Changing Paradigms in Moderate-to-Severe Psoriasis – Dr. Norman Wasel
- Unmet Needs of Psoriasis and The Promise of Biologics – Dr. Kristian Reich
- Remicade Infusion Network: Experience in the Rheumatology Community – Dr. Kam Shojania

2:00 – 3:30 From Trial to Clinic: A Year of Raptiva Experience in Canada

Room: Macdonald ABCD, Fairmont Chateau Whistler Resort

Session Objectives:

Following this workshop, the attendee will be able to:

- Define the appropriate patients for biological agents
- Apply practical considerations in the use of biologics for the treatment of psoriasis, with a focus on Raptiva
- Review the efficacy and safety of Raptiva as observed in Canadian clinical practice

Faculty:

1. Charles Lynde, MD FRCPC – Chair/Moderator, Intro & Close
2. Richard Langley MC FRCPC – Raptiva: Suitable for a Wide Range of Psoriasis Patients
3. Norm Wasel, MD FRCPC – Clinical Cases With Raptiva (Canadian Perspective)
4. Kim Papp, MD PhD FRCPC – Expert Panel Discussion

2:00 – 3:30 **From Trial to Clinic: A Year of Raptiva Experience in Canada** (*continued...*)

Program:

Clinical use of biologic therapies is changing the way dermatologists are treating moderate-to-severe psoriasis. As physicians gain experience with these agents, they are learning practical tips on which agents are best for which patients and why, and on how to optimally use each agent. This program is directed to the practicing dermatologist who treats patients with moderate to severe psoriasis. Topics covered will discuss:

- ✓ How to select an appropriate agent for a patient (with a focus on selecting patients appropriate for treatment with Raptiva) – based on different patient profiles
- ✓ Practical guidelines for treating patients with Raptiva, using Canadian case histories.

Friday, October 27, 2006

9:30 – 11:00 **New Advances in Photobiology and Photoprotection**

Room: Frontenac C, Fairmont Chateau Whistler Resort

Faculty:

Dr Robert Bissonnette
Anny Fourtanier
Dominique Moyal
Jean Louis Refregier
Dr Jason Rivers

Agenda and objectives:

To be advised

11:30 – 1:30 **Biologics and Psoriatic Disease: Practical Management Issues and Clinical Update**

Room: Macdonald ABCD, Fairmont Chateau Whistler Resort

Session Objectives:

Dermatologists participating in this symposium will;

- Discuss practical management issues with biologic agents in the treatment of psoriatic disease based on extensive US experience,
- Recognize the key safety issues with TNF antagonists currently available in Canada,
- Obtain pearls on how to incorporate biologics into their own practice through an interactive panel discussion

11:30 – 1:30 Biologics and Psoriatic Disease: Practical Management Issues and Clinical Update (*continued...*)

Faculty:

Richard Thomas, MD (Vancouver, British Columbia)
Joseph Jorizzo, MD (Winston-Salem, North Carolina)
Richard Langley, MD (Halifax, Nova Scotia)

Agenda:

11:30	Introduction, Learning Objectives, Pre-Assessment (touchpads)	Richard Thomas, MD
11:40	Biologics: Practical Management Issues (US Experience)	Joseph Jorizzo, MD
12:20	Safety Update: TNF Antagonists	Richard Langley, MD
13:00	Panel Discussion	
13:25	Post-Assessment and Closing Remarks	
13:30	Adjourn	